Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC).

(2017) M. C. Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract 4154: Multi-parameter molecular characterization of circulating tumor cells (CTC): Development of a CTC-endocrine therapy index (CTC-ETI)

(2014) Costanza Paoletti et al.   CANCER RESEARCH

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study

(2012) V. Georgoulias et al.   ANNALS OF ONCOLOGY

Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients

(2011) Brigitte Rack et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients

(2011) Antonio Giordano et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract S6-5: Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients

(2011) B Rack et al.   CANCER RESEARCH

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy

(2010) F.- C. Bidard et al.   ANNALS OF ONCOLOGY

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

(2010) Tanja Fehm et al.   BREAST CANCER RESEARCH AND TREATMENT

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients

(2010) Marie-Christine Etienne-Grimaldi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

(2010) S. Riethdorf et al.   CLINICAL CANCER RESEARCH

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

(2009) F.-C. Bidard et al.   ANNALS OF ONCOLOGY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer

(2009) Seigo Nakamura et al.   Breast Cancer

Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial

(2008) J.-Y. Pierga et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications

(2007) F. Nole et al.   ANNALS OF ONCOLOGY